

**The Health Service (Benefit) (Limited List)  
(Pharmaceutical Benefit) (Amendment No. 5)  
Regulations, 2018**

<i>Made</i>	31st July, 2018
<i>Coming into operation</i>	1st August, 2018
<i>Laid before the States</i>	, 2018

**THE COMMITTEE FOR EMPLOYMENT & SOCIAL SECURITY**, in exercise of the powers conferred on it by sections 10 and 35 of the Health Service (Benefit) (Guernsey) Law, 1990<sup>a</sup>, section 1 of the Health Service (Benefit) (Limited Lists) Ordinance, 2004<sup>b</sup> and all other powers enabling it in that behalf, hereby makes the following Regulations:-

---

<sup>a</sup> Ordres en Conseil Vol. XXXII, p. 192; Vol. XLIII(1), p. 246; Order in Council No. II of 2011; Recueil d'Ordonnances Tome XXVI, pp. 177, 483, and 495; Tome XXIX, pp. 182, 373, 406 and 580 and modified by Tome XXVI, pp. 484 and 491 and 495; Tome XXVII, p. 200; Tome XXVIII, p. 1; Tome XXIX, pp. 182, 196, 200 and 210; Tome XXXI, p. 628 and Tome XXXII, p. 628, Ordinance No. XXXIV of 2013, and Ordinance No. XXV of 2017. Extended to Alderney with modification by Recueil d'Ordonnances Tome XXV, p. 204.

<sup>b</sup> Recueil d'Ordonnances Tome XXIX, p. 441.

**Amendment to the 2004 Regulations.**

1. In the Schedule to the Health Service (Benefit) (Limited List) (Pharmaceutical Benefit) Regulations, 2004<sup>c</sup>,

(a) insert the rows set out in Schedule 1 to these Regulations in the appropriate places under the appropriate headings, as set out in that Schedule, and

(b) delete the row set out in Schedule 2 to these Regulations.

**Interpretation.**

2. (1) In these Regulations, unless the context requires otherwise –

"**enactment**" includes a Law, an Ordinance and any subordinate legislation and includes any provision or portion of a Law, an Ordinance or any subordinate legislation, and

"**subordinate legislation**" means any regulation, rule, order, rule of court, resolution, scheme, byelaw or other instrument made under any statutory, customary or inherent power and having legislative effect, but does not include an Ordinance.

(2) Any reference in these Regulations to an enactment is a reference thereto as from time to time amended, re-enacted (with or without modification), extended or applied.

---

<sup>c</sup> G.S.I. No. 9 of 2004 as amended by G.S.I. No. 42 of 2004; No's 18, 25 and 38 of 2005; No's 11, 18, 26, 36 and 46 of 2006; No's 3, 5, 6, 16, 17 and 32 of 2007; No's 11, 23, 29, 31, 47, 50 and 76 of 2008; No's 16, 35, 43, 47 and 56 of 2009; No's 5, 32, 48, 88, 91 and 99 of 2010; No's 5, 13, 19, 37, 38 and 52 of 2011; No's 5, 25, 33 and 52 of 2012; No's 5, 27, 35, 42, 68, 78 and 87 of 2013; No's 8, 11, 16, 25, 57, 69 and 99 of 2014, No's 9, 33 and 106 of 2015, No's. 10, 17, 25, 31 and 49 of 2016; No's. 48, 69, 78, 88 and 117 of 2017, and No's. 6, 9, 16 and 28 of 2018.

(3) The Interpretation (Guernsey) Law, 1948<sup>d</sup> applies to the interpretation of these Regulations.

**Citation, commencement and extent.**

3. (1) These Regulations may be cited as the Health Service (Benefit) (Limited List) (Pharmaceutical Benefit) (Amendment No. 5) Regulations, 2018, and shall come into force on the 1st day of August, 2018.

(2) These Regulations shall have effect in the Islands of Guernsey, Alderney, Herm and Jethou.

Dated this 31st day of July, 2018.



M. K. LE CLERC

President of the States Committee for Employment & Social Security

For and on behalf of the Committee

---

<sup>d</sup> Ordres en Conseil Vol. XIII, p. 355.

## SCHEDULE 1

ROW TO BE INSERTED IN THE SCHEDULE TO THE 2004 REGULATIONS

British National Formulary (BNF) Section	Heading	Pharmaceutical Benefit
10.1.3	Rheumatic Disease Suppressants	Apremilast 10mg , 20mg , 30mg tablets (For local specialist initiation only)
9.5	Minerals	Magnesium (as magnesium glycerophosphate) 97.2mg (4 mmol) tablets, chewable tablets.
5.3	Antivirals	Glecaprevir/pibrentasvir 100mg/40mg tablets (Maviret) (To be dispensed by PEH pharmacy only and when prescribed by publically-funded Consultant Virologist only)

SCHEDULE 2

ROW TO BE DELETED FROM THE SCHEDULE TO THE 2004 REGULATIONS

British National Formulary (BNF) Section	Heading	Pharmaceutical Benefit
9.5	Minerals	Magnesium glycerophosphate - Caps 500mg

---

**EXPLANATORY NOTE**

*(This note is not part of the Regulations)*

These Regulations add a number of drugs to the list of drugs that may be prescribed as pharmaceutical benefit and remove one drug from that list.

These Regulations came into force on the 1st day of August, 2018.